• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Intestinal Cancer - Pipeline Review, H2 2012 Product Image

Intestinal Cancer - Pipeline Review, H2 2012

  • Published: December 2012
  • 412 pages
  • Global Markets Direct

Intestinal Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Intestinal Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Intestinal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intestinal Cancer. Intestinal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Intestinal Cancer.
- A review of the Intestinal Cancer products under development by companies and universities/research institutes READ MORE >

2
List of Tables 7
List of Figures 13
Introduction 14
REPORT COVERAGE 14
Intestinal Cancer Overview 15
Therapeutics Development 16
An Overview of Pipeline Products for Intestinal Cancer 16
Intestinal Cancer Therapeutics under Development by Companies 18
Intestinal Cancer Therapeutics under Investigation by Universities/Institutes 31
Late Stage Products 49
Comparative Analysis 49
Mid Clinical Stage Products 50
Comparative Analysis 50
Early Clinical Stage Products 51
Comparative Analysis 51
Discovery and Pre-Clinical Stage Products 52
Comparative Analysis 52
Intestinal Cancer Therapeutics – Products under Development by Companies 53
Intestinal Cancer Therapeutics – Products under Investigation by Universities/Institutes 70
Companies Involved in Intestinal Cancer Therapeutics Development 106
Johnson & Johnson 106
F. Hoffmann-La Roche Ltd. 107
Kyowa Hakko Kirin Co., Ltd. 108
Abbott Laboratories 109
Amgen Inc. 110
AstraZeneca PLC 111
Eli Lilly and Company 112
Viralytics Ltd. 113
GlaxoSmithKline plc 114
Bioniche Life Sciences, Inc. 115
Tekmira Pharmaceuticals Corp. 116
Gilead Sciences, Inc. 117
Daiichi Sankyo Company, Ltd 118
AbGenomics International, Inc. 119
Oxford BioMedica plc 120
YM BioSciences Inc. 121
Celltrion, Inc. 122
Prolexys Pharmaceuticals, Inc. 123
Bio-Path Holdings, Inc. 124
BioSante Pharmaceuticals, Inc. 125
Histogen, Inc. 126
Novartis AG 127
Geistlich Pharma AG 128
Aphios Corporation 129
Astellas Pharma Inc. 130
Chong Kun Dang Pharmaceutical 131
Eisai Co., Ltd. 132
Nippon Kayaku Co., Ltd. 133
Taiho Pharmaceutical Co., Ltd. 134
Teva Pharmaceutical Industries Limited 135
Yakult Honsha Co., Ltd. 136
Enzon Pharmaceuticals, Inc. 137
Alfacell Corporation 138
Bayer AG 139
4SC AG 140
Neogenix Oncology Corporation 141
Alchemia Limited 142
EntreMed, Inc. 143
Celldex Therapeutics, Inc. 144
Enzo Biochem, Inc. 145
AEterna Zentaris Inc. 146
ImmunoCellular Therapeutics, Ltd. 147
IMMUNOMEDICS, INC 148
Idera Pharmaceuticals, Inc. 149
Lorus Therapeutics Inc 150
Bio-Bridge Science, Inc. 151
Bionomics Limited 152
Neuren Pharmaceuticals Limited 153
Northwest Biotherapeutics, Inc. 154
Novogen Limited 155
Cleveland BioLabs, Inc. 156
Compugen Ltd. 157
Paladin Labs Inc. 158
Patrys Limited 159
Critical Outcome Technologies Inc. 160
Curis, Inc. 161
Cytokinetics, Inc 162
Telik, Inc. 163
Poniard Pharmaceuticals, Inc. 164
Regeneron Pharmaceuticals, Inc. 165
Dendreon Corporation 166
Choongwae Pharma Corp 167
Green Cross Corporation 168
MOLOGEN AG 169
Innocell Corporation 170
CrystalGenomics, Inc. 171
BioAlliance Pharma SA 172
Sareum Holdings plc 173
Transgene Biotek Ltd 174
Rexahn Pharmaceuticals, Inc. 175
MabVax Therapeutics, Inc. 176
Oryzon 177
Antisense Pharma GmbH 178
Chipscreen Biosciences Ltd 179
Supratek Pharma Inc. 180
Bionucleon Srl 181
Actinium Pharmaceuticals, Inc. 182
Actis Biologics, Inc 183
Multimmune GmbH 184
Nerviano Medical Sciences S.r.l. 185
Med Discovery SA 186
immatics biotechnologies GmbH 187
Provecs Medical GmbH 188
Alethia Biotherapeutics Inc. 189
Coronado Biosciences, Inc. 190
MacroGenics, Inc. 191
ACT Biotech, Inc. 192
OncoMed Pharmaceuticals, Inc. 193
PledPharma AB 194
Boston Biomedical, Inc. 195
DanDrit Biotech A/S 196
PDS Biotechnology Corporation 197
AlphaVax, Inc. 198
Azaya Therapeutics, Inc. 199
Merrimack Pharmaceuticals, Inc. 200
CritiTech, Inc. 201
Deciphera Pharmaceuticals, LLC 202
ProNAi Therapeutics, Inc. 203
Mersana Therapeutics, Inc. 204
Affichem 205
Advenchen Laboratories, LLC 206
MolMed S.p.A. 207
Pharminox Limited 208
NovaLead Pharma Pvt. Ltd. 209
Vaccinogen, Inc. 210
Globeimmune, Inc. 211
Etubics Corporation 212
NewLink Genetics Corporation 213
Taiwan Liposome Company 214
Cellceutix Corporation 215
TVAX Biomedical, LLC 216
CG Therapeutics, Inc. 217
Quintessence Biosciences, Inc. 218
Tautatis Incorporated 219
CureTech Ltd. 220
Lipopharma 221
Nereus Pharmaceuticals, Inc. 222
Viventia Biotechnologies Inc. 223
AVEO Pharmaceuticals, Inc. 224
Merus B.V. 225
Pique Therapeutics 226
Cancer Therapeutics CRC Pty Ltd 227
Isofol Medical AB 228
ISU ABXIS Co.,Ltd. 229
Jiangsu Kanion Pharmaceutical Co., Ltd. 230
Celtic Pharmaceutical Holdings L.P. 231
VectorLogics, Inc. 232
Gliknik, Inc. 233
EyeGene, Inc. 234
ISA Pharmaceuticals B.V. 235
Regulon Inc. 236
ImQuest Life Sciences 237
TAU Therapeutics, LLC 238
Gradalis Inc. 239
FunZyme BioTechnologies S.A. 240
CytomX, LLC. 241
Intestinal Cancer – Therapeutics Assessment 242
Assessment by Monotherapy Products 242
Assessment by Combination Products 243
RPI-4610 - Drug Profile 244
GM-CT-01 - Drug Profile 245
OncoVAX - Drug Profile 247
rosuvastatin calcium - Drug Profile 249
aspirin - Drug Profile 250
5-Fluorouracil + Leucovorin Calcium + Oxaliplatin + Bevacizumab - Drug Profile 252
CAPOX + Bevacizumab - Drug Profile 254
Bev-FOLFOX - Drug Profile 256
FOLF-CB - Drug Profile 258
Erbitux + BMS-582664 - Drug Profile 260
cetuximab - Drug Profile 262
Panitumumab - Drug Profile 263
Carboplatin + 5-Fluorouracil + Leucovorin - Drug Profile 264
Fluorouracil + Folinic Acid + Capecitabine - Drug Profile 266
FOLFOX-4 + Cetuximab - Drug Profile 268
Cetuximab + FOLFIRI - Drug Profile 270
Radiation Therapy + Fluorouracil + Mitomycin C + Cisplatin - Drug Profile 272
5-Fluorouracil + L-Leucovorin - Drug Profile 274
Eflornithine + Sulindac - Drug Profile 275
tegafur + uracil - Drug Profile 276
Fluorouracil + Levamisole Hydrochloride - Drug Profile 277
Fluorouracil + Leucovorin + Levamisole - Drug Profile 278
5-Fluorouracil + Leucovorin + Radiation Therapy - Drug Profile 280
Fluorouracil + Leucovorin Calcium 1 - Drug Profile 282
Capecitabine + Oxaliplatin - Drug Profile 283
Fluorouracil + Semustine + Vincristine - Drug Profile 284
UFT + Krestin - Drug Profile 286
UFT + Leucovorin + Krestin - Drug Profile 287
Tegafur + Uracil + Leucovorin + Polysaccharide-K - Drug Profile 289
OxCap + Panitumumab - Drug Profile 291
Hepatic Arterial Infusion 5-FU + FOLFOX + Bevacizumab - Drug Profile 293
Propranolol + Etodolac - Drug Profile 295
OxMdG + Panitumumab - Drug Profile 296
Brivanib + Erbitux - Drug Profile 298
5-Fluorouracil + Folinic Acid + CPT-11 - Drug Profile 300
S-1 + Oxaliplatin - Drug Profile 302
5-Fluorouracil + Uracil-Tegafur + Leucovorin - Drug Profile 304
Tegafur + Uracil + Krestin - Drug Profile 306
Uracil + Tegafur + Leucovorin - Drug Profile 307
XELOXA-A - Drug Profile 308
Cisplatin + Fluorouracil + Mitomycin C + Radiation Therapy - Drug Profile 310
Oxaliplatin + FluoroPyrimidine + Panitumumab - Drug Profile 311
Oxaliplatin + Leucovorin Calcium + 5-FU - Drug Profile 313
Bevacizumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin Calcium + Oxaliplatin - Drug Profile 315
C225 + Fluorouracil + Irinotecan Hydrochloride + Leucovorin Calcium - Drug Profile 317
Floxuridine + Dexamethasone + Leucovorin - Drug Profile 319
Bevacizumab + Fluorouracil + Irinotecan Hydrochloride + Leucovorin Calcium + Oxaliplatin - Drug Profile 321
Bevacizumab + FOLFOX Regimen + Capecitabine + Fluorouracil + Leucovorin Calcium + Oxaliplatin - Drug Profile 324
FOLFOX Regimen + Fluorouracil + Leucovorin Calcium + Oxaliplatin - Drug Profile 327
FOLFIRI - Drug Profile 329
5-Fluorouracil + Isovorin - Drug Profile 331
Avastin + Tarceva - Drug Profile 332
FOLFOX 4 - Drug Profile 335
Ropivacaine + Opioid - Drug Profile 336
Lubiprostone + PEG - Drug Profile 337
Tegafur-Uracil + Leucovorin Calcium - Drug Profile 338
Intestinal Cancer Therapeutics – Drug Profile Updates 339
Intestinal Cancer Therapeutics – Discontinued Products 350
Intestinal Cancer Therapeutics - Dormant Products 357
Intestinal Cancer – Product Development Milestones 401
Featured News & Press Releases 401
Appendix 407
Methodology 407
Coverage 407
Secondary Research 407
Primary Research 407
Expert Panel Validation 407
Contact Us 408
Disclaimer 408

List of Tables
Number of Products Under Development for Intestinal Cancer, H2 2012 20
Products under Development for Intestinal Cancer – Comparative Analysis, H2 2012 21
Number of Products under Development by Companies, H2 2012 23
Number of Products under Development by Companies, H2 2012 (Contd..1) 24
Number of Products under Development by Companies, H2 2012 (Contd..2) 25
Number of Products under Development by Companies, H2 2012 (Contd..3) 26
Number of Products under Development by Companies, H2 2012 (Contd..4) 27
Number of Products under Development by Companies, H2 2012 (Contd..5) 28
Number of Products under Development by Companies, H2 2012 (Contd..6) 29
Number of Products under Development by Companies, H2 2012 (Contd..7) 30
Number of Products under Development by Companies, H2 2012 (Contd..8) 31
Number of Products under Development by Companies, H2 2012 (Contd..9) 32
Number of Products under Development by Companies, H2 2012 (Contd..10) 33
Number of Products under Development by Companies, H2 2012 (Contd..11) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 40
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 41
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 42
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 45
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 46
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 47
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 48
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 49
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 50
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 51
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 52
Comparative Analysis by Late Stage Development, H2 2012 53
Comparative Analysis by Mid Clinical Stage Development, H2 2012 54
Comparative Analysis by Early Clinical Stage Development, H2 2012 55
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 56
Products under Development by Companies, H2 2012 57
Products under Development by Companies, H2 2012 (Contd..1) 58
Products under Development by Companies, H2 2012 (Contd..2) 59
Products under Development by Companies, H2 2012 (Contd..3) 60
Products under Development by Companies, H2 2012 (Contd..4) 61
Products under Development by Companies, H2 2012 (Contd..5) 62
Products under Development by Companies, H2 2012 (Contd..6) 63
Products under Development by Companies, H2 2012 (Contd..7) 64
Products under Development by Companies, H2 2012 (Contd..8) 65
Products under Development by Companies, H2 2012 (Contd..9) 66
Products under Development by Companies, H2 2012 (Contd..10) 67
Products under Development by Companies, H2 2012 (Contd..11) 68
Products under Development by Companies, H2 2012 (Contd..12) 69
Products under Development by Companies, H2 2012 (Contd..13) 70
Products under Development by Companies, H2 2012 (Contd..14) 71
Products under Development by Companies, H2 2012 (Contd..15) 72
Products under Development by Companies, H2 2012 (Contd..16) 73
Products under Investigation by Universities/Institutes, H2 2012 74
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 75
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 76
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 77
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 78
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 79
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 80
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 81
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 82
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 83
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 84
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 85
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 86
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 87
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 88
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 89
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 90
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 91
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 92
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 93
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 94
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 95
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 96
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 97
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 98
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 99
Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 100
Products under Investigation by Universities/Institutes, H2 2012 (Contd..27) 101
Products under Investigation by Universities/Institutes, H2 2012 (Contd..28) 102
Products under Investigation by Universities/Institutes, H2 2012 (Contd..29) 103
Products under Investigation by Universities/Institutes, H2 2012 (Contd..30) 104
Products under Investigation by Universities/Institutes, H2 2012 (Contd..31) 105
Products under Investigation by Universities/Institutes, H2 2012 (Contd..32) 106
Products under Investigation by Universities/Institutes, H2 2012 (Contd..33) 107
Products under Investigation by Universities/Institutes, H2 2012 (Contd..34) 108
Products under Investigation by Universities/Institutes, H2 2012 (Contd..35) 109
Johnson & Johnson, H2 2012 110
F. Hoffmann-La Roche Ltd., H2 2012 111
Kyowa Hakko Kirin Co., Ltd., H2 2012 112
Abbott Laboratories, H2 2012 113
Amgen Inc., H2 2012 114
AstraZeneca PLC, H2 2012 115
Eli Lilly and Company, H2 2012 116
Viralytics Ltd., H2 2012 117
GlaxoSmithKline plc, H2 2012 118
Bioniche Life Sciences, Inc., H2 2012 119
Tekmira Pharmaceuticals Corp., H2 2012 120
Gilead Sciences, Inc., H2 2012 121
Daiichi Sankyo Company, Ltd, H2 2012 122
AbGenomics International, Inc., H2 2012 123
Oxford BioMedica plc, H2 2012 124
YM BioSciences Inc., H2 2012 125
Celltrion, Inc., H2 2012 126
Prolexys Pharmaceuticals, Inc., H2 2012 127
Bio-Path Holdings, Inc., H2 2012 128
BioSante Pharmaceuticals, Inc., H2 2012 129
Histogen, Inc., H2 2012 130
Novartis AG, H2 2012 131
Geistlich Pharma AG, H2 2012 132
Aphios Corporation, H2 2012 133
Astellas Pharma Inc., H2 2012 134
Chong Kun Dang Pharmaceutical, H2 2012 135
Eisai Co., Ltd., H2 2012 136
Nippon Kayaku Co., Ltd., H2 2012 137
Taiho Pharmaceutical Co., Ltd., H2 2012 138
Teva Pharmaceutical Industries Limited, H2 2012 139
Yakult Honsha Co., Ltd., H2 2012 140
Enzon Pharmaceuticals, Inc., H2 2012 141
Alfacell Corporation, H2 2012 142
Bayer AG, H2 2012 143
4SC AG, H2 2012 144
Neogenix Oncology Corporation, H2 2012 145
Alchemia Limited, H2 2012 146
EntreMed, Inc., H2 2012 147
Celldex Therapeutics, Inc., H2 2012 148
Enzo Biochem, Inc., H2 2012 149
AEterna Zentaris Inc., H2 2012 150
ImmunoCellular Therapeutics, Ltd., H2 2012 151
IMMUNOMEDICS, INC, H2 2012 152
Idera Pharmaceuticals, Inc., H2 2012 153
Lorus Therapeutics Inc, H2 2012 154
Bio-Bridge Science, Inc., H2 2012 155
Bionomics Limited, H2 2012 156
Neuren Pharmaceuticals Limited, H2 2012 157
Northwest Biotherapeutics, Inc., H2 2012 158
Novogen Limited, H2 2012 159
Cleveland BioLabs, Inc., H2 2012 160
Compugen Ltd., H2 2012 161
Paladin Labs Inc., H2 2012 162
Patrys Limited, H2 2012 163
Critical Outcome Technologies Inc., H2 2012 164
Curis, Inc., H2 2012 165
Cytokinetics, Inc, H2 2012 166
Telik, Inc., H2 2012 167
Poniard Pharmaceuticals, Inc., H2 2012 168
Regeneron Pharmaceuticals, Inc., H2 2012 169
Dendreon Corporation, H2 2012 170
Choongwae Pharma Corp, H2 2012 171
Green Cross Corporation, H2 2012 172
MOLOGEN AG, H2 2012 173
Innocell Corporation, H2 2012 174
CrystalGenomics, Inc., H2 2012 175
BioAlliance Pharma SA, H2 2012 176
Sareum Holdings plc, H2 2012 177
Transgene Biotek Ltd, H2 2012 178
Rexahn Pharmaceuticals, Inc., H2 2012 179
MabVax Therapeutics, Inc., H2 2012 180
Oryzon, H2 2012 181
Antisense Pharma GmbH, H2 2012 182
Chipscreen Biosciences Ltd, H2 2012 183
Supratek Pharma Inc., H2 2012 184
Bionucleon Srl, H2 2012 185
Actinium Pharmaceuticals, Inc., H2 2012 186
Actis Biologics, Inc, H2 2012 187
Multimmune GmbH, H2 2012 188
Nerviano Medical Sciences S.r.l., H2 2012 189
Med Discovery SA, H2 2012 190
immatics biotechnologies GmbH, H2 2012 191
Provecs Medical GmbH, H2 2012 192
Alethia Biotherapeutics Inc., H2 2012 193
Coronado Biosciences, Inc., H2 2012 194
MacroGenics, Inc., H2 2012 195
ACT Biotech, Inc., H2 2012 196
OncoMed Pharmaceuticals, Inc., H2 2012 197
PledPharma AB, H2 2012 198
Boston Biomedical, Inc., H2 2012 199
DanDrit Biotech A/S, H2 2012 200
Assessment by Monotherapy Products, H2 2012 246
Assessment by Combination Products, H2 2012 247
Intestinal Cancer Therapeutics – Drug Profile Updates 343
Intestinal Cancer Therapeutics – Discontinued Products 354
Intestinal Cancer Therapeutics – Discontinued Products (Contd..1) 355
Intestinal Cancer Therapeutics – Discontinued Products (Contd..2) 356
Intestinal Cancer Therapeutics – Discontinued Products (Contd..3) 357
Intestinal Cancer Therapeutics – Discontinued Products (Contd..4) 358
Intestinal Cancer Therapeutics – Discontinued Products (Contd..5) 359
Intestinal Cancer Therapeutics – Discontinued Products (Contd..6) 360
Intestinal Cancer Therapeutics – Dormant Products 361
Intestinal Cancer Therapeutics – Dormant Products (Contd..1) 362
Intestinal Cancer Therapeutics – Dormant Products (Contd..2) 363
Intestinal Cancer Therapeutics – Dormant Products (Contd..3) 364
Intestinal Cancer Therapeutics – Dormant Products (Contd..4) 365
Intestinal Cancer Therapeutics – Dormant Products (Contd..5) 366
Intestinal Cancer Therapeutics – Dormant Products (Contd..6) 367
Intestinal Cancer Therapeutics – Dormant Products (Contd..7) 368
Intestinal Cancer Therapeutics – Dormant Products (Contd..8) 369
Intestinal Cancer Therapeutics – Dormant Products (Contd..9) 370
Intestinal Cancer Therapeutics – Dormant Products (Contd..10) 371
Intestinal Cancer Therapeutics – Dormant Products (Contd..11) 372
Intestinal Cancer Therapeutics – Dormant Products (Contd..12) 373
Intestinal Cancer Therapeutics – Dormant Products (Contd..13) 374
Intestinal Cancer Therapeutics – Dormant Products (Contd..14) 375
Intestinal Cancer Therapeutics – Dormant Products (Contd..15) 376
Intestinal Cancer Therapeutics – Dormant Products (Contd..16) 377
Intestinal Cancer Therapeutics – Dormant Products (Contd..17) 378
Intestinal Cancer Therapeutics – Dormant Products (Contd..18) 379
Intestinal Cancer Therapeutics – Dormant Products (Contd..19) 380
Intestinal Cancer Therapeutics – Dormant Products (Contd..20) 381
Intestinal Cancer Therapeutics – Dormant Products (Contd..21) 382
Intestinal Cancer Therapeutics – Dormant Products (Contd..22) 383
Intestinal Cancer Therapeutics – Dormant Products (Contd..23) 384
Intestinal Cancer Therapeutics – Dormant Products (Contd..24) 385
Intestinal Cancer Therapeutics – Dormant Products (Contd..25) 386
Intestinal Cancer Therapeutics – Dormant Products (Contd..26) 387
Intestinal Cancer Therapeutics – Dormant Products (Contd..27) 388
Intestinal Cancer Therapeutics – Dormant Products (Contd..28) 389
Intestinal Cancer Therapeutics – Dormant Products (Contd..29) 390
Intestinal Cancer Therapeutics – Dormant Products (Contd..30) 391
Intestinal Cancer Therapeutics – Dormant Products (Contd..31) 392
Intestinal Cancer Therapeutics – Dormant Products (Contd..32) 393
Intestinal Cancer Therapeutics – Dormant Products (Contd..33) 394
Intestinal Cancer Therapeutics – Dormant Products (Contd..34) 395
Intestinal Cancer Therapeutics – Dormant Products (Contd..35) 396
Intestinal Cancer Therapeutics – Dormant Products (Contd..36) 397
Intestinal Cancer Therapeutics – Dormant Products (Contd..37) 398
Intestinal Cancer Therapeutics – Dormant Products (Contd..38) 399
Intestinal Cancer Therapeutics – Dormant Products (Contd..39) 400
Intestinal Cancer Therapeutics – Dormant Products (Contd..40) 401
Intestinal Cancer Therapeutics – Dormant Products (Contd..41) 402
Intestinal Cancer Therapeutics – Dormant Products (Contd..42) 403
Intestinal Cancer Therapeutics – Dormant Products (Contd..43) 404

List of Figures
Number of Products under Development for Intestinal Cancer, H2 2012 20
Products under Development for Intestinal Cancer – Comparative Analysis, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 35
Late Stage Products, H2 2012 53
Mid Clinical Stage Products, H2 2012 54
Early Clinical Stage Products, H2 2012 55
Discovery and Pre-Clinical Stage Products, H2 2012 56
Assessment by Monotherapy Products, H2 2012 246
Assessment by Combination Products, H2 2012 247

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos